摘要
目的 观察乳腺癌新辅助化疗（NAC）前后cyclin D1表达情况，探讨其与化疗效果之间的关系。方法 选择84例乳腺癌患者经空心针穿刺获取组织学样本并加以验证，经3～4个周期ET方案[吡柔比星（THP）＋多西紫杉醇（TXT）]NAC，采用免疫组织化学Envision二步法检测化疗前、后cyclinD1的表达变化情况。结果 84例患者中 完全缓解（CR）4例（4.76 %）（其中病理CR 2例），部分缓解（PR）54例（64.29 %），稳定（SD）26例（30.95 %），无疾病进展（PD）患者。NAC后乳腺癌组织中cyclin D1表达降低[ 65.48 %（55／84）]，与化疗前[39.29 %（33／84）]相比，差异有统计意义（χ2＝11.55，P＝0.001）。NAC后cyclin D1阳性表达转为阴性表达者临床缓解率[86.36 %（19／22）]高于未转为阴性表达者[45.45 %（15／33）]，差异有统计学意义（χ2＝9.359，P＝0.002）。结论 NAC降低乳腺癌组织中的cyclinD1表达，且NAC后cyclin D1表达转阴者化疗效果提高，可以评估NAC的有效性。
Objective To evaluate the effect of neoadjuvant chemotherapy （NAC） by investigating the expression of cyclin D1 in human breast cancer before and after NAC. Methods Eighty-four cases of breast cancer were diagnosed by core biopsies. The expression level of cyclin D1 in cancer tissues was measured by immunohistochemical envision two-step method before and after NAC （pirarubicin and docetaxel regimen for 3-4 cycles）. Results Complete remission （CR） occurred in 4 cases of 84 patients （4.76 %） with 2 pathological complete response cases, partial response （PR） in 54 cases （64.29 %）, stability （SD） in 26 cases （30.95 %） and no disease progression （PD） patients. The positive rate of cyclin D1 in cancer tissues [65.48 % （55/84）] was significantly decreased after NAC [39.29 % （33/84）] （χ2 = 11.55, P = 0.001）. In clinical level, the ease rate was significantly improved in patients whose cyclin D1 expression switched from positive [86.36 % （19/22）] to negative [45.45 % （15/33）] after NAC treatment （χ2 = 9.359, P = 0.002）. Conclusion NAC significantly decreases the expression of cyclin D1 in breast cancer tissues. Meanwhile, the ease rate is improved when cyclin D1 expression switched from positive to negative after NAC. Therefore, cyclin D1 expression can be used as an evaluation index for the efficiency of NAC.
出处
《肿瘤研究与临床》
CAS
2013年第7期458-459,462,共3页
Cancer Research and Clinic
